Trial Profile
A Phase II Trial of Dasatinib (BMS-354825) in Advanced Hepatocellular Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2018
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 18 Oct 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 20 Nov 2012 Status changed from completed to recruiting as reported by ClinicalTrials.gov record.
- 14 Jun 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.